Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq delivered a keynote speech on the landscape of gastrointestinal tumor detection and diagnosis during the conference. To conclude, Zhao said that Geneseeq and聽Zai Lab聽hope to use this strategic collaboration as the cornerstone to combine resources of both companies to provide high-quality cancer diagnostics and treatment solutions. I look forward to further joint actions between the two parties to improve cancer patient outcomes and generate positive societal impact.

William Liang, Chief Commercial Officer of聽Zai Lab and President of Greater China said: “In recent years, advances in genetic testing technology have boosted the continuous improvement of precision medicine and treatment programs.聽Zai Lab聽has three products listed in聽China with 10-15 more products expected to be approved. Many of them rely on biomarker testing. We hope to work with genetic testing partners to help patients achieve precise and personalized treatment. At the same time, we also look forward to working with these partners to improve the efficiency of drug research and development, shorten the development cycle, and accelerate product approvals.”

The companies look forward to a strong alliance in providing more accurate and efficient treatment plans for patients.

The post Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.